Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis

Table 1

Primary characteristics of the eligible studies in more detail.

Author (year)	Phase	No. of patients		Male, (%)		Age, mean (SD)		COPD severity, (%)
								Severe		Very severe
		Roflumilast	Placebo	Roflumilast	Placebo	Roflumilast	Placebo	Roflumilast	Placebo	Roflumilast	Placebo
Calverley PM (2007)	IV	1,178	1,174	821 (70)	794 (68)	64 (8.8)	65 (8.4)	508 (67)	510 (68)	181 (24)	176 (23)
Calverley PM (2009)	IV	973	972	718 (74)	725 (75)	65 (8.4)	65 (8.4)	943 (61)	989 (64)	463 (30)	440 (28)
Rennard SI (2011)	IV	30	11	NR	NR	64 (7.4)	70 (6.8)	356 (63)	399 (66)	148 (26)	169 (28)
De Backer W (2014)	III	567	606	387 (68)	400 (66)	64 (8.7)	64 (8.8)	NR	NR	NR	NR
Martinez FJ (2015)	III	1,537	1,154	1,150 (75)	1,186 (76)	64 (9.0)	64 (9.0)	678 (70)	677 (70)	291 (30)	273 (28)
Martinez FJ (2016)	III	760	753	571 (75)	574 (76)	65 (9.6)	64 (9.1)	698 (59)	720 (61)	474 (40)	446 (38)

NR: no report.